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Abstract 14 
Current research indicates that exogenous stem cells may accelerate reparative 15 
processes in joint disease. However, no previous studies have evaluated whether bone marrow 16 
cells (BMCs) target the injured cranial cruciate ligament (CCL) in dogs. The objective of this 17 
study was to investigate engraftment of BMCs following intra-articular injection in dogs with 18 
spontaneous CCL injury. Autologous PKH26-labeled BMCs were injected into the stifle joint 19 
of eight client-owned dogs with CCL rupture. The effects of PKH26 staining on cell viability 20 
and PKH26 fluorescence intensity were analyzed in vitro using a MTT assay and flow 21 
cytometry. Labelled BMCs in injured CCL tissue were identified using fluorescence 22 
microscopy of biopsies harvested 3 and 13 days after intra-articular BMC injection.  23 
 24 
The intensity of PKH26 fluorescence declines with cell division but was still 25 
detectable after 16 days. Labelling with PKH26 had no detectable effect on cell viability or 26 
proliferation. Only rare PKH26-positive cells were present in biopsies of the injured CCL in 27 
3/7 dogs and in synovial fluid in 1/7 dogs. No differences in transforming growth factor-β1, 28 
and interleukin-6 before and after BMC treatment were found and no clinical complications 29 
were noted during a 1 year follow-up period. In conclusion, BMCs were shown to engraft to 30 
the injured CCL in dogs when injected into the articular cavity. Intra-articular application of 31 
PKH26-labeled cultured mesenchymal stem cells is likely to result in higher numbers of 32 
engrafted cells that can be tracked using this method in a clinical setting. 33 
 34 
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The cranial cruciate ligament (CCL) is essential for stifle joint stability and its rupture 39 
leads to functional impairment, meniscal lesions and early onset of osteoarthritis (Arnoczky 40 
and Marshall, 1977; Korvick et al., 1994). In dogs, CCL injury is common and has been 41 
treated using a variety of different surgical techniques since 1952 (Paatsama, 1952), but no 42 
single treatment option has been shown to be clearly superior. The goals of most reported 43 
techniques are to alleviate pain, decrease instability and minimize osteoarthritis (OA) (Moore 44 
and Read, 1995), but residual lameness is frequent and OA is a common sequel (Elkins et al., 45 
1991; Innes et al., 2004; Rayward et al., 2004). The lack of ideal outcome following surgery 46 
has prompted interest in exploring new adjunctive treatment options, such as regenerative 47 
stem cell therapy. Knowledge of the benefits of these treatment strategies would be useful 48 
both for the treatment of spontaneous canine CCL injury and for investigations into 49 
degenerative anterior cruciate ligament (ACL) disease in humans using the dog as a model. 50 
 51 
Mesenchymal stem cell (MSC) therapy is a newly developing therapeutic approach in 52 
OA that has proven useful in cartilage repair in a variety of animal models (Black et al., 2007, 53 
2008; Chong et al., 2007; Guercio et al., 2012; Jorgensen and Noel, 2012; Khan et al., 2010; 54 
Kirkby and Lewis, 2012; Koga et al., 2008; Mokbel et al., 2011a, b; Murphy et al., 2003). 55 
Bone marrow-derived MSCs hold particular promise for tissue repair because of their ability 56 
to engraft into tissues and differentiate into the target tissue cell type, including fibroblasts, 57 
osteocytes, adipocytes, chondrocytes and myocytes (Chamberlain et al., 2007; Pittenger et al., 58 
1999). In recent studies, MSCs were found to accelerate healing of transected ligaments in 59 
animal models (Agung et al., 2006; Kanaya et al., 2007; Kim et al., 2011) and evidence 60 
suggests that fresh whole bone marrow cells (BMCs) may have superior effects compared to 61 
purified MSCs, presumably because of an additional benefit of hematopoietic stem cells (Oe 62 
 
 
et al., 2011). Indeed, injured rat ACLs treated with BMCs had more mature fibroblasts and 63 
tighter collagen bundles compared to those treated with MSCs, leading the authors to 64 
conclude that bone marrow (BM) transplantation is an effective treatment for ACL injury (Oe 65 
et al., 2011). To date, no studies have investigated the potential benefit of stem cell adjunctive 66 
treatment in dogs with experimental or spontaneous CCL injury. 67 
 68 
 The purpose of the present study was to assess the engraftment potential of autologous 69 
BMCs injected into the articular cavity in dogs with partial or complete CCL rupture and to 70 
determine whether PKH26 red fluorescent labelling is a safe and effective way to track canine 71 
BMCs.  72 
 73 
Material and methods 74 
Animals 75 
Client-owned dogs presented for surgical treatment of spontaneous partial or complete 76 
CCL rupture to the Division of Small Animal Surgery and Orthopaedics of the University of 77 
Berne were considered for inclusion in the study (see Appendix: Supplementary data for 78 
details). Informed client consent was obtained for each dog. Study inclusion criteria were 79 
diagnosis of partial or complete CCL rupture confirmed by arthroscopy and unremarkable 80 
results of routine haematological and serum biochemical analyses. Dogs were excluded if 81 
there was a recent history of illness other than pelvic limb lameness or if they had undergone 82 
previous intra-articular application of any substance or previous surgery on the affected limb. 83 
Dogs were screened using an orthopaedic examination with various parameters: lameness, 84 
functional disability, range of motion and pain on manipulation. For each parameter a score 85 
was recorded at first time of presentation and 3 month after surgery. The scores assigned were 86 
 
 
based on a 4-point scale, 0 (no/best) to 4 (worst) (For details see appendix: Supplementary 87 
material). 88 
 89 
All animal experiments were reviewed and approved by the Commission of Animal 90 
Experimentation of the Canton of Berne, Switzerland (BE42/12; date of approval, 30/4/2012).  91 
 92 
Isolation of bone marrow cells 93 
Bone marrow was harvested from the proximal humerus in each dog using a 13-G BM 94 
biopsy needle connected to a 10-mL syringe containing 2 mL of heparin solution (3,000 95 
U/mL). A total of 15 mL BM was aspirated and immediately injected into a transfer bag 96 
containing 7 mL citrate phosphate dextrose adenine solution. The BM aspirate was passed 97 
through a blood transfer filter set into a 20-mL syringe, and cells were separated by density 98 
gradient centrifugation at 445 g for 35 min. The interface with the nucleated cell fraction was 99 
transferred and washed twice in phosphate buffered saline (PBS) before counting and 100 
partitioning for PKH26 labelling, intra-articular injection, and cultivation (See Appendix: 101 
Supplementary material for details). 102 
 103 
Flow cytometric characterization of cells 104 
Freshly isolated cells and cultured cells were evaluated by flow cytometry for the 105 
specific MSC markers, CD90 (YKIX337.217, eBioscience) and CD44 (FAB5449A, R&D), 106 
and for the hematopoietic stem cell marker, CD45 (YKIX716.13, eBioscience). Data were 107 
analyzed using a flow cytometer (LSR II, BD Bioscience) and commercial software 108 




PKH26 labelling 111 
 Labelling of cell membranes was performed using the PKH26 Red Fluorescence Kit 112 
(Sigma-Aldrich) according to the manufacturer’s instructions. After staining, a portion of 113 
PKH26-BMCs was resuspended in PBS at a concentration of 1 × 107 cells/mL for intra-114 
articular injection. In addition, stained cells were suspended in complete medium for 115 
evaluation of dye cytotoxicity, growth characteristics and fluorescence intensity. 116 
 117 
Evaluation of PKH26 cytotoxicity 118 
The effect of PKH26 labelling on cell viability was tested using a colorimetric MTT 119 
assay. For this, MSCs from the second passage were stained with PKH26 dye at 2 × 10-120 
6M/106 cells and 4 × 10-6M/106 cells. The assay was conducted in replicate with MSCs from 121 
four dogs as described elsewhere (Waldherr et al., 2012). Cell viability in each well, measured 122 
as the optical density (OD), was calculated as follows: 100 × (OD of sample well – OD of 123 
blank well)/(OD of control well – OD of blank well). Mean values of repeated measurements 124 
were used for analysis. 125 
 126 
Population doubling time 127 
Growth characteristics of MSCs at the first and second passages unstained and stained 128 
with PKH26 (2 × 10-6 M and 4 × 10-6 M) from six dogs were investigated. The MSCs were 129 
seeded into a 24-well plate at a density of 2.1 × 103 cells/cm2. After a recovery time of 48 h, 130 
three wells were detached daily for a period of 8 days and cell numbers were counted in a 131 
hemocytometer. The population doubling time was computed using an online calculator1. 132 
1 See: http://www.doubling-time.com/compute.php (accessed 15 August 2014) 
 
 
                                                 
 133 
 134 
PKH26 fluorescence intensity 135 
Fluorescence intensity was assessed in freshly isolated BMCs and MSCs during cell 136 
proliferation over 16 days as described in detail in the Appendix: Supplementary material.  137 
 138 
In vivo experimental protocol 139 
The experimental schedule is summarized in Fig. 1. On day 0, dogs presenting with 140 
signs of CCL injury were clinically examined. BM was harvested and pre-operative 141 
radiographs were performed under general anaesthesia. BMCs were isolated and labelled with 142 
PKH26 (final concentration: 2 × 10-6 M PKH26 and 1 × 107 cells/mL) within 3 h of 143 
harvesting. Synovial fluid was first aspirated and a total of 1 × 107 PKH26-labeled BMCs 144 
diluted in 1 mL PBS was injected immediately afterwards through the same needle under 145 
aseptic conditions. An aliquot of remaining BMCs was used for microbiological quality 146 
control. The dogs were then presented again for stifle arthroscopy and tibial plateau levelling 147 
osteotomy (TPLO) either 13 days (Group 1) or 3 days (Group 2) following intra-articular 148 
BMC injection. Prior to arthroscopy, synovial fluid was again collected. 149 
 150 
Tissue collection 151 
During arthroscopy immediately prior to surgical treatment by TPLO, the gross 152 
appearance of the stifle joint was evaluated and biopsies of the damaged CCL and synovial 153 
membrane were excised. Synovial membrane was harvested craniomedially and 154 
craniolaterally to the optic port that was located lateral to the patellar ligament halfway 155 
between patella and tibial tuberosity. Tissues were snap frozen on dry ice in O.C.T. 156 
 
 
compound (Tissue-Tek). Each block was cut into 5 µm sections at 10 µm intervals and placed 157 
on specimen slides. Sections were stored at -80 °C pending fluorescence microscopy. 158 
 159 
Fluorescence microscopy of harvested samples 160 
Slides were examined for PKH26 fluorescence using a confocal laser scanning 161 
fluorescence microscope (FluoView FV1000, Olympus) after counterstaining with TOTO-3 162 
iodide (Life Technologies). Sections were defined as positive if a clear cell structure with 163 
spindle-shaped fibroblast-like morphology was detected showing at least partial red 164 
fluorescence in the membrane and far red fluorescence of the nucleus. Synovial fluid samples 165 
were examined for PKH26 fluorescence after centrifugation in a 96-well plate. 166 
 167 
Synovial fluid analyses 168 
Because of a possible effect of BMCs on cytokine production and immune cell 169 
attraction, synovial fluid obtained before and after intra-articular BM injection was examined 170 
cytologically, and transforming growth factor (TGF)-β1 and interleukin (IL)-6 were 171 
quantified using a commercial ELISA (canine TGF-ß1, IL-6 Quantikine ELISA Kit, R&D) 172 
according to the manufacturer´s protocol. 173 
 174 
Follow-up examinations 175 
Dogs were discharged from hospital 1 day after surgery with a soft-padded bandage on 176 
the operated leg for 3 days and administered carprofen (Rimadyl, Pfizer, 4 mg/kg PO once 177 
daily for 7 days). Owners were instructed to restrict activity initially to leash walks, followed 178 
by a gradual increase in activity. Dogs were re-examined 14 days and 3 months after surgery. 179 
The same clinician carried out both initial and follow-up orthopaedic and clinical 180 
 
 
examinations. In addition, a final follow-up inquiry with the owners was performed by 181 
telephone 12 months after surgery. Complications, including infection, pain or worsening of 182 
articular function were recorded during follow-up examinations. 183 
 184 
Statistical analyses 185 
For each donor and experimental condition at least triplicate samples were used for 186 
each assessment unless otherwise stated. Statistical analysis was performed with NCSS 2007 187 
software. Differences in population doubling time, TGF-ß1 and IL-6 were evaluated using a 188 





Eight cases were initially included, but one was subsequently excluded because it was 194 
not presented for arthroscopy as scheduled. Four dogs underwent arthroscopy 13 days after 195 
injection. Because of a low rate of detected PKH26 positive cells the interval between BMC 196 
transplantation and tissue harvesting was shortened, therefore the second group of three dogs 197 
went to surgery 3 days after injection (Fig. 1). 198 
 199 
Isolation, cultivation and flow cytometric characterization of cells 200 
The mean value of nucleated cell fraction recovered after BM aspiration (eight dogs) 201 
and density gradient centrifugation was 23.0 × 107 cells (range, 0.35-33.2 × 107 cells). Freshly 202 
isolated BMCs stained largely positive for CD45 with only a small proportion (<1%) of cells 203 
 
 
negative for CD45 and double positive for CD44 and CD90. Cultured cells were adherent 204 
within 2 to 3 days showing spindle-shaped fibroblast-like morphology generating 205 
subsequently colony-forming units. After 8 to 15 days in culture, colonies became confluent 206 
and were passaged for the first time. Primary cultured cells (second and fifth passages) 207 
stained on average 92% ± 5% positive for CD44, 45% ± 3% double positive for CD44 and 208 
CD90, and 100% negative for CD45 on flow cytometry, confirming phenotype consistent 209 
with MSCs in most cells. Lack of expression of CD45 on cultured cells indicated that cells of 210 
haematopoietic origin had been excluded during cell culture. 211 
 212 
Evaluation of PKH26 cytotoxicity 213 
The colorimetric MTT assay performed on MSCs from the 2nd passage in four dogs 214 
revealed that the mean relative number of viable MSCs 24 h after PKH26 staining compared 215 
to unstained MSCs was 93.4% ± 3.5% at 2 x 10-6 M and 98.6% ± 9.2% at 5 x 10-6 M PKH26. 216 
 217 
Population doubling time 218 
Mean population doubling time of unlabelled MSCs and PKH26-labeled MSCs from 6 219 
dogs was 146.7 ± 63.5 h (range, 44.5-238.0 h) and 107.2 ± 37.5 h (range, 43.0-173.0 h), 220 
respectively. No significant difference was found between these population doubling times by 221 
using a paired samples t-test (P = 0.43). 222 
 223 
PKH26 fluorescence intensity 224 
Labelled BMCs plated in culture dishes attached efficiently and showed uniformly 225 
distributed red fluorescence on microscopy. The labelling rate of BMCs assessed by flow 226 
cytometry was 97.3 ± 3.3% and labelling intensity decreased to 67.5 ± 8.3% at the end of the 227 
 
 
16-day observation period. The labelling rates of second passage MSCs assessed by flow 228 
cytometry on days 0 and 16 were 94.0 ± 2.1% and 15.1 ± 4.6%, respectively, with a mean 229 
number of cell divisions after 16 days of 8 ± 3. 230 
 231 
Fluorescent microscopy of harvested samples 232 
Fluorescence microscopy of control CCL tissue co-cultivated with PKH26-labelled 233 
BMCs revealed adhesion and migration of BMCs based on numerous red fluorescent cells 234 
located superficially and within the tissue (Fig. 2; positive control). Tissue of CCL and 235 
synovial membrane were obtained from seven dogs after BMCs transplantation. A total of 236 
280 sections (40 sections per dog) of CCL and synovial membrane were examined for PKH26 237 
fluorescence. Positive cells were only detected in eight slides from three dogs of which one 238 
were sampled 3 days after BMC injection and two were sampled 13 days after BMC injection 239 
(Fig. 3). Positive cells were located within the organized CCL tissue and arranged 240 
predominantly as single cells and occasionally in groups. However, the numbers of positive 241 
cells was extremely small with no more than 10 per section. The intensity of PKH26-positive 242 
cells was clearly less in these samples than in ex vivo CCL samples co-cultured with PKH26-243 
labeled BMCs. A single synovial sample (harvested on day 3) showed PKH26 positive cells. 244 
 245 
Synovial fluid analyses 246 
Cytological examination of synovial fluid taken both prior to BMC injection and prior 247 
to arthroscopy exhibited less than 5% neutrophils. No significant difference was found in 248 
TGF-ß1 (P = 0.21) and IL-6 (P = 0.29) concentrations between samples harvested prior to and 249 




Clinical assessment and follow-up of study dogs 252 
Pre-operative arthroscopy of BMC-treated dogs revealed no gross changes in the stifle 253 
joint other than those generally observed in dogs assessed for partial or complete CCL 254 
rupture. Bacteriological cultures of the remaining portion of injected BMC preparations 255 
revealed no growth in all samples. 256 
 257 
Follow-up examination performed 3 months after surgery revealed mild lameness and 258 
swelling of the knee joint in one dog. The other dogs showed improvement of lameness, 259 
function, and pain on manipulation (see Appendix: Supplementary material). Four dogs had 260 
improved scores when testing the range of motion but withdrew the affected leg at full range 261 
manipulation. A final inquiry was performed in all dogs 12 months after surgery. Normal 262 
activity was reported by all owners during these inquires. The owners of three dogs indicated 263 
slight stiffness in the morning. No complications associated with the intra-articular injection 264 
of the PKH26-labeled BMCs were observed in any of the dogs. 265 
 266 
Discussion 267 
Several previous studies have investigated the effects of intra-articular stem cell 268 
application on cartilage in dogs with OA (Black et al., 2007, 2008; Guercio et al., 2012; 269 
Mokbel et al., 2011a). However, most previous reports have focused on clinical outcome. 270 
This study evaluated engraftment of fluorescent-labelled BMCs into injured ligaments when 271 
applied into the articular cavity in dogs with spontaneous CCL injury. The decision to use 272 
BMCs instead of MSCs was based on ease of processing, making the procedure practical for 273 
future use in a clinical setting, as well as the potential additional benefit of BMCs based on 274 




Several pre-conditions of harvested cells were tested in order to ensure that the 277 
selected study design was applicable regarding dye and cells. Separated BMCs of the eight 278 
dogs comprise haematopoetic stem cells showing CD45+ which were the main fraction with 279 
around 99% and a very small part of mesenchymal stem cells which showed a phenotype of 280 
CD45- CD44+ and CD90+. These findings are in accordance with the findings of Alvarez-281 
Viejo et al. (2013).  282 
 283 
Following cultivation, cells were replaced by a homologous layer of adherent cells 284 
expressing putative surface specific antigens, such as CD44+ and CD90+ as markers for 285 
MSCs and lacking the haematopoetic stem cell marker CD45. They presented MSC 286 
characteristics as reported in other studies (Csaki et al., 2007; Kisiel et al., 2012). Lack of 287 
expression of CD45+ on cultured MSCs indicated that cells of haematopoietic origin had been 288 
excluded during the cell culture process. Cell numbers recovered following gradient 289 
centrifugation varied between samples, but were largely similar to those previously reported 290 
in dogs (Nishida et al., 2012; Sato et al., 2011). Likewise, in vitro growth potential varied 291 
between dogs, demonstrated by the wide range in population doubling time. These results are 292 
consistent with previously published data for humans and may reflect patient variability 293 
(Bertolo et al., 2013), age-related replicative senescence (Mareschi et al., 2006; Zhou et al., 294 
2008), as well as variation in individual MSC differentiation potency (Ding et al., 2013). 295 
 296 
The ability to track cells is undoubtedly necessary to evaluate the potential of cell 297 
migration and new tissue transformation after in vivo transplantation. Differentiation between 298 
graft and host cells after transplantation requires a method that labels cells of interest and 299 
identifies them after harvesting at a later time. Previous studies used BMCs or MSCs 300 
 
 
expressing green fluorescent protein (GFP) injected into the injured stifle joints of dogs 301 
(Mokbel et al., 2011a), donkeys (Mokbel et al., 2011b) and goats (Murphy et al., 2003), as 302 
well as GFP transgenic animals (Oe et al., 2011). An advantage of using GFP is its potential 303 
use in long-term studies as daughter cells adopt GFP gene expression and, with it, 304 
fluorescence is multiplied after several cell divisions. However, use of GFP requires a gene 305 
transfer agent, such as a virus that is non-integrating or, preferably from a biosafety point of 306 
view, a non-viral vector. These, however, are limited by the requirement of large cell 307 
numbers, high levels of cell death and low transfection efficiency (Bakhshandeh et al., 2012).  308 
 309 
The transformation procedures for GFP labelling are time consuming, making its use 310 
impractical for implantation of autologous freshly isolated cells. Given this and some ethical 311 
considerations as to potential adverse effects of GFP-modified cells, its use was considered 312 
inappropriate for cell tracking in client-owned dogs. Instead, we used PKH26 red fluorescent 313 
dye, a lipophilic cell membrane stain that has previously been used for tracking of a variety of 314 
different cell types (Wisenberg et al., 2009). Data in the present study showed that cell 315 
viability and population doubling time of MSCs in culture was not significantly affected by 316 
PKH26 staining, corroborating findings of a previously reported study in which no effect on 317 
cell growth or proliferation was observed (Shao-Fang et al., 2011). Furthermore, we 318 
demonstrated that PKH26 labelling was highly effective and fluorescence was strong in 319 
BMCs co-cultured with CCL tissue for 16 days. However, progressive loss of fluorescence 320 
was observed in cultured MSCs over the same time frame. These findings suggest that BMCs 321 
attached to tissue ex vivo do not proliferate as quickly as in monolayers due to their incipient 322 




The findings of the present study, using the dog as a model of spontaneous CCL 325 
rupture, confirm previous observations in rats with transected ACL, showing that BMCs 326 
injected into the articular cavity engraft to the injured site of the ACL (Oe et al., 2011). In 327 
rats, GFP-transduced cells were found to be present in high numbers in the transected 328 
ligaments and seemed to be involved in appreciable neoligamental tissue transformation after 329 
4 weeks. However, we were only able to detect a very small number of PKH26 positive cells 330 
in a few CCL biopsies in 3/7 dogs. This may be due to the very low numbers of MSCs, 331 
estimated as 1 MSC per 104 mononuclear cells, which can differentiate into tissue in the 332 
transplanted BM as well as a low survival rate after in vivo transplantation (Pittenger et al., 333 
1999; Wexler and Donaldson, 2003). 334 
 335 
Currently, no data are available with regard to the numbers of cells that can be safely 336 
transplanted into articular cavities in the dog. In previous studies, numbers of injected cells 337 
varied between 1.4 and 5 × 106 MSCs in different articular cavities in dogs (Black et al., 2007, 338 
2008; Guercio et al., 2012; Mokbel et al., 2011a) and 1 × 107 MSCs were injected into goat 339 
articular cavity without adverse effects (Murphy et al., 2003). Based on this empirical data, 340 
we injected 1 × 107 BMCs in the hope of achieving sufficient numbers of MSCs without 341 
untoward effects. Larger numbers of BMCs may result in higher numbers of engrafted MSCs, 342 
but further studies are needed to assess the safety and efficiency of larger transplants in dogs.  343 
 344 
Furthermore, a limitation in the evaluation of tissue samples in our study was the 345 
inability to obtain full-thickness biopsies in clinical patients. The small size of biopsies may 346 
therefore have led to some false negative results. Finally, in contrast to GFP expression, the 347 
fluorescence of PKH26 labelling decreases with cell division. The numbers of cells and time 348 
point at which labelled cells are assessed is therefore crucial for cell tracking. However, we 349 
 
 
did not find a significantly greater number of PKH26 positive biopsies harvested 3 days 350 
compared to those harvested 13 days after intra-articular BM injection. 351 
 352 
Previous findings of enhanced ACL healing were associated with increased TGF-ß1 353 
concentrations in synovial fluid and ACL material in rats treated with intra-articular BMCs 354 
(Oe et al., 2011). Secretion of TGF-ß1 is directly influenced by the transplanted cells (Kuroda 355 
et al., 2000). TGFb1 plays an anabolic role in the healing of ligaments by accelerating 356 
proteoglycan synthesis and cell proliferation. However, the concentrations of TGF-ß1 357 
measured prior to and after intra-articular BMC treatment in dogs in the present study were 358 
not significantly different. Moreover, a possible inflammatory response after cell 359 
transplantation was tested by analysing IL-6. IL-6 produced by several cell types functions to 360 
increase the number of inflammatory cells in synovial tissue and its production is stimulated 361 
by IL-1 and/or TNF (Venn et al., 1993). Our results revealed no inflammatory response after 362 
BMC injection. IL-6 levels were no different prior to and after transplantation. For the 363 
interpretation of the data, however, it should be noted that our results are based on a small 364 
sample size.  365 
 366 
Conclusions 367 
Fresh BMCs injected into the articular cavity in dogs with spontaneous CCL injury 368 
can engraft in the injured CCL, but were only rarely detected using this procedure. The low 369 
recovery of transplanted cells implies that application of MSCs may be more useful for cell 370 
tracking after PKH26 labelling in a clinical setting. Overall, BMC transplantation into the 371 
stifle joint was well tolerated and showed no undesirable clinical effects on dogs followed for 372 
up to 1 year. The clinical procedure was found to be practical and safe, but a decrease in 373 
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Figure legends 559 
Fig. 1. Timetable of the study design. Group 1 underwent the long procedure, group 2 the 560 
shortened procedure. TPLO, Tibia plateau levelling osteotomy.  561 
 562 
Fig. 2. Fluorescence photomicrographs of control tissues showing PKH26 positive (red) and 563 
TOTO-3 positive (grey) cells (B, D); A and C are corresponding photomicrographs merged 564 
with tissue. Control samples were made from tissues of CCL obtained from dogs undergoing 565 
surgical treatment for CCL disease without intra-articular BM injection. Positive control 566 
tissues were made by co-cultivation of tissue with PKH26-labeled BMCs at a density of 1 × 567 
106cells/cm2 in 12-well plates containing complete medium, harvested after 8 (C, D) and 16 568 
(A, B) days and processed in an identical manner as study samples. Labelled cells were 569 
associated with the surface (C, D) and were also integrated within the CCL explant (A, B). 570 
Magnification: × 100. 571 
 572 
Fig. 3. Fluorescence photomicrographs showing PKH26 positive (red) and TOTO-3 positive 573 
(grey) cells (B, D); merged with tissue (A, C). In vivo specimens of torn CCLs from two dogs 574 
at day 13 after transplantation of PKH26-labelled autologous BMCs. Labelled cells were 575 
detected within the CCLs. Magnification: × 100. 576 
 577 
Fig. 4. Scatter blot of concentrations of TGF-ß1 and IL-6 in synovial fluid sampled prior to 578 
and post BMC transplantation in seven dogs. Samples of synovial fluid were collected from 579 
all dogs on day 0 before BMC transplantation, additionally from dogs of group 1 (plotting 580 
symbol: circle, black) on day 13 and of group 2 (plotting symbol: triangle, grey) at day 3 after 581 
BMC transplantation. A median smooth line of the seven dogs is presented. 582 
 
 
